Aptevo Therapeutics Inc. Cost of Revenue
Aptevo Therapeutics Inc. (APVO) reported Cost of Revenue of $19.93 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-25.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2020-03-25
- Aptevo Therapeutics Inc. cost of goods and services sold for the quarter ending 2019-12-31 was $6.14M, a 37.52% increase year-over-year.
- Aptevo Therapeutics Inc. cost of goods and services sold for the quarter ending 2019-09-30 was $3.96M, a 62.45% increase year-over-year.
- Aptevo Therapeutics Inc. cost of goods and services sold for the quarter ending 2019-06-30 was $5.99M, a 136.19% increase year-over-year.
- Aptevo Therapeutics Inc. cost of goods and services sold for the quarter ending 2019-03-31 was $3.85M, a 116.00% increase year-over-year.
- Aptevo Therapeutics Inc. cost of goods and services sold for fiscal 2019 was $19.93M, a 77.70% increase from fiscal 2018.
- Aptevo Therapeutics Inc. cost of goods and services sold for fiscal 2018 was $11.21M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2019-12-31 | $6.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $10.10M derived: sum of 2 quarters · filed 2020-03-25 | $16.08M derived: sum of 3 quarters · filed 2020-03-25 | $19.93M 10-K · filed 2020-03-25 |
| 2019-09-30 | $3.96M 10-Q · filed 2019-11-07 | $9.94M derived: sum of 2 quarters · filed 2019-11-07 | $13.79M 10-Q · filed 2019-11-07 | $18.25M derived: sum of 4 quarters · filed 2020-03-25 |
| 2019-06-30 | $5.99M 10-Q · filed 2019-08-09 | $9.83M 10-Q · filed 2019-08-09 | $14.29M derived: sum of 3 quarters · filed 2020-03-25 | $16.73M derived: sum of 4 quarters · filed 2020-03-25 |
| 2019-03-31 | $3.85M 10-Q · filed 2019-05-09 | $8.31M derived: sum of 2 quarters · filed 2020-03-25 | $10.75M derived: sum of 3 quarters · filed 2020-03-25 | $13.28M derived: sum of 4 quarters · filed 2020-03-25 |
| 2018-12-31 | $4.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $6.90M derived: sum of 2 quarters · filed 2020-03-25 | $9.43M derived: sum of 3 quarters · filed 2020-03-25 | $11.21M 10-K · filed 2020-03-25 |
| 2018-09-30 | $2.44M 10-Q · filed 2019-11-07 | $4.97M derived: sum of 2 quarters · filed 2019-11-07 | $6.75M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $2.53M 10-Q · filed 2019-08-09 | $4.32M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $1.78M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |